Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
McKesson stock has delivered a very strong 336.0% return over the past five years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) model both still point to the shares trading below their estimated worth.
Over 5 years, McKesson has returned 336.0%, which puts recent share price moves in the context of a long and very strong run.
Expectations for McKesson's ability to keep converting revenue into reliable cash flows can support the valuation. At the same time, any pressure on reimbursement terms or healthcare pricing may weigh on what investors are willing to pay.
Across the broader checks, McKesson screens as undervalued in 5 of 6 areas, which leans toward the stock being cheap rather than fully priced.
For investors, the debate is whether McKesson's recent share price still leaves enough gap to the intrinsic value estimate to justify viewing it as a potential undervaluation story.
Find out why McKesson's 19.3% return over the last year is lagging behind its peers.
The Discounted Cash Flow (DCF) approach values McKesson based on the cash it is expected to generate for shareholders over time. For McKesson, the model uses latest twelve month free cash flow of about $6.0b and assumes that cash flows keep growing rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $1,675 per share.
Compared with the current market price, this DCF estimate implies the stock trades at roughly a 49.9% discount to its calculated worth. The model therefore suggests McKesson stock screens as undervalued, with the market price not fully reflecting the level and projected growth of its cash generation.
On these cash flow projections, McKesson appears undervalued relative to the DCF based intrinsic value estimate.
Our Discounted Cash Flow (DCF) analysis suggests McKesson is undervalued by 49.9%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for McKesson.
The P/E multiple is a useful way to cross check how McKesson is valued against its earnings power. McKesson currently trades on a P/E of about 21.3x. This sits below the Healthcare industry average of roughly 25.2x and also below the peer group average of about 22.8x.
The valuation framework used here suggests a fair P/E ratio for McKesson of around 31.4x, based on its profile, margins, growth expectations and risks. Compared with the current 21.3x, there is a sizeable gap, which indicates that the stock price may not fully reflect the earnings that the company is generating relative to sector benchmarks.
On this earnings multiple check, McKesson stock appears undervalued.
See what the numbers say about this price — find out in our valuation breakdown.
Simply Wall St Narratives for McKesson pick up where this valuation puzzle leaves off and spell out which assumptions about McKesson's future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today's price on the market. Each Narrative treats fair value as a thesis about the business that you can track over time. They sit on Simply Wall St's Community page for ongoing reference.
You can be one of the first voices in the Simply Wall St community to set out a clear, numbers based Narrative on McKesson, and a view on where its growth, margins and execution go from here. Share your thesis, track how it plays out as new results arrive and see how other investors respond over time.
Do you think there's more to the story for McKesson? Head over to our Community to see what others are saying!
For McKesson, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple checks point in the same direction and indicate the stock screens as undervalued. The key judgment from here is whether the company can keep converting its scale into consistent cash generation that justifies that intrinsic value estimate. If reimbursement pressure or healthcare pricing changes limit those cash flows, the current discount may prove warranted. The crux of the debate is whether the current gap between price and intrinsic value reflects an opportunity or a fair reflection of the risks tied to McKesson's future cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MCK.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]